Werry Tim D, Christopoulos Arthur, Sexton Patrick M
Howard Florey Institute, University of Melbourne, Parkville, Melbourne, VIC, Australia.
Curr Pharm Des. 2006;12(14):1683-702. doi: 10.2174/138161206776873725.
Control of cell growth and differentiation has long been a focus of intense research interest, particularly in the context of cancer therapeutics. The evolutionarily-conserved extracellular signal-regulated kinases 1 and 2 (ERK1/2) are serine-threonine kinases that respond to a wide range of mitogens and growth factors to initiate changes in cellular proliferation and differentiation, and are the most important members of the mitogen-activated protein kinase (MAPK) family in terms of seven transmembrane-domain receptor (7TMR)-mediated regulation of mitogenic processes. Regulation of the ERK1/2 signaling cascade by 7TMRs is highly complex and cell type-specific. Recent advances in our knowledge of this effector pathway have revealed that its regulation is at least partly independent of traditional G protein-mediated actions arising from the stimulation of 7TMRs. This review summarizes the current position of our knowledge of ERK1/2 regulation, and illustrates the wealth of potential targets available for the development of new strategies for the treatment of proliferative and other ERK-related disorders.
细胞生长和分化的控制长期以来一直是深入研究的热点,尤其是在癌症治疗领域。进化上保守的细胞外信号调节激酶1和2(ERK1/2)是丝氨酸 - 苏氨酸激酶,它们对多种促有丝分裂原和生长因子作出反应,以启动细胞增殖和分化的变化,并且就七跨膜结构域受体(7TMR)介导的促有丝分裂过程的调节而言,是丝裂原活化蛋白激酶(MAPK)家族中最重要的成员。7TMR对ERK1/2信号级联的调节高度复杂且具有细胞类型特异性。我们对这条效应通路认识的最新进展表明,其调节至少部分独立于由7TMR刺激产生的传统G蛋白介导的作用。本综述总结了我们目前对ERK1/2调节的认识状况,并阐述了开发治疗增殖性疾病和其他与ERK相关疾病新策略时可用的大量潜在靶点。